Log In
BCIQ
Print this Print this
 

DMUC5754A

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionAntibody-drug conjugate (ADC) composed of a humanized IgG1 mAb against mucin 16 (MUC16; CA125) and monomethyl auristatin E (MMAE)
Molecular Target Mucin 16 (MUC16) (CA125)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationOvarian cancer
Indication DetailsTreat advanced recurrent platinum-resistant ovarian cancer
Regulatory Designation
PartnerRoche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today